[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363375-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363375-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","somatic-copy-number-alterations-profiling-in-non-small-cell-lung-cancer-and-their-correlation-with-clinical-efficacy-in-first-line-treatment","Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment","","Immune checkpoint inhibitors remain standard first-line therapy for advanced NSCLC without actionable genomic alterations, yet many patients do not benefit. High somatic copy number alteration (SCNA) burden has been linked to reduced ICI outcomes, but its predictive relevance for chemotherapy or combination regimens is unclear. This study analyzes SCNA burden across first-line ICI, chemotherapy, and ICI plus chemotherapy using shallow whole-genome sequencing, linking genomic features to clinical efficacy and tumor microenvironment characteristics.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/somatic-copy-number-alterations-profiling-in-non-small-cell-lung-cancer-and-their-correlation-with-clinical-efficacy-in-first-line-treatment/363375/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/somatic-copy-number-alterations-profiling-in-non-small-cell-lung-cancer-and-their-correlation-with-clinical-efficacy-in-first-line-treatment/363375.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient groups and treatments were evaluated in the study?","Question",{"text":63,"@type":64},"The study included 258 patients with advanced NSCLC treated first-line with immune checkpoint inhibitors, chemotherapy, or a combination of both.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was SCNA burden quantified in this research?",{"text":68,"@type":64},"Tumor DNA was analyzed by shallow whole-genome sequencing, and SCNA burden was quantified as the fraction of the genome altered at chromosomal arm and whole-chromosome level (FGAa+c).",{"name":70,"@type":61,"acceptedAnswer":71},"What was the main relationship between SCNA burden and clinical efficacy?",{"text":72,"@type":64},"High SCNA burden was significantly associated with diminished progression-free survival in patients treated with ICI, while it was not associated with PFS in chemotherapy or combination treatment groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363375,1790544614,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Priano etal. Genome Medicine (2026) 18:60  \n[https://doi.org/10.1186/s13073-026-01637-7](https://doi.org/10.1186/s13073-026-01637-7)  \nGenome Medicine  \nRESEARCH Open Access  \nSomatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment  \nIlaria Priano 1,2, Ramon Amat1, Caterina Carbonell1, Aina Arbusà-Roca1, Patricia Iranzo 1,2, Nuria Pardo 1,2, Mireia Soleda1, Gerard Romero-Sola 1, Barbara Sinigaglia1, Sara Polo-Alonso 1, Ana Callejo1,2, Augusto Valdivia1,2, Pedro Rocha1,2, Javier Hernandez-Losa3, Marta Sese3, Oriol Mirallas 1,2, Laura Masfarré1,2, Susana Cedrés1,2, Alex Martinez-Marti1,2, Rocío Caro-Consuegra1* and Enriqueta Felip1,2*  \nAbstract  \nBackground Immune checkpoint inhibitors (ICI) are the current standard-of-care first-line treatment for advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations. Yet some patients do not achieve clinical benefit, underscoring the need for predictive biomarkers. High burden of somatic copy number alterations (SCNAs), including chromosomal arm-and whole-chromosome-level changes, has been linked to reduced benefit from  \nICI. However, its predictive value in chemotherapy or combination regimens remains largely unexplored. Here, we evaluated SCNA burden across multiple first-line treatment strategies in a cohort of patients with NSCLC.  \nMethods We assembled a cohort of 258 patients with advanced NSCLC treated with first-line ICI (n = 86), chemotherapy (ChT; n = 107), or a combination of both (ICI + ChT; n = 65) . Tumor DNA was analyzed using shallow whole-genome sequencing (sWGS) . SCNA burden was quantified as the fraction of the genome altered at the chromosomal arm and whole-chromosome level (FGAa+c) . We performed Kaplan-Meier and Cox regression analyses to assess its value across treatment groups. Additionally, we examined associations between recurrent SCNAs, clinical efficacy, and tumor microenvironment (TME) features using data from The Cancer Genome Atlas (TCGA) .  \nResults High SCNA burden (FGAa+c > 4 . 25) was significantly associated with diminished progression-free survival (PFS) in patients treated with ICI (p-val = 0 . 0097) . In contrast, FGAa+c did not associate with PFS following ChT  \n(p-val = 0.9566) or ICI + ChT (p-val = 0.6472). Specific SCNAs in chromosome 9p were independently associated with reduced ICI benefit (p-val = 0 . 0469), even after adjusting for FGAa+c (p-val = 0 . 0229) . This SCNA was negatively associated with immune infiltration in theTME and was linked to differences in the immune cell type composition.  \n*Correspondence: Rocío Caro-Consuegra [rociocaro@vhio.net](rociocaro@vhio.net)[ ](rociocaro@vhio.net)Enriqueta Felip[efelip@vhio.net](efelip@vhio.net)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-n","cbCainqWd1HO4EHA","https://ap.wps.com/l/cbCainqWd1HO4EHA","pdf",4255727,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"What patient groups and treatments were evaluated in the study?\",\"answer\":\"The study included 258 patients with advanced NSCLC treated first-line with immune checkpoint inhibitors, chemotherapy, or a combination of both.\"},{\"question\":\"How was SCNA burden quantified in this research?\",\"answer\":\"Tumor DNA was analyzed by shallow whole-genome sequencing, and SCNA burden was quantified as the fraction of the genome altered at chromosomal arm and whole-chromosome level (FGAa+c).\"},{\"question\":\"What was the main relationship between SCNA burden and clinical efficacy?\",\"answer\":\"High SCNA burden was significantly associated with diminished progression-free survival in patients treated with ICI, while it was not associated with PFS in chemotherapy or combination treatment groups.\"}]","Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment | PDF",1790150994,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89d99233f403235db33ee39a0e9ee38a.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a916dd9b040ded9bc20f05ff1b18ec65.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d560ea7e199833c38a5bb299c8a474b.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72e443a5d678a8250ed73f339052443c.webp",980,1306]